Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) – Research analysts at First Analysis issued their Q3 2018 EPS estimates for Tabula Rasa Healthcare in a note issued to investors on Monday. First Analysis analyst anticipates that the company will earn $0.15 per share for the quarter. First Analysis has a “Overweight” rating and a $41.00 price target on the stock.

Tabula Rasa Healthcare (NASDAQ:TRHC) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.08 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.02. Tabula Rasa Healthcare had a negative net margin of 2.27% and a negative return on equity of 5.58%. The firm had revenue of $33.27 million for the quarter, compared to analysts’ expectations of $31.76 million. During the same quarter in the prior year, the company posted $0.06 earnings per share. The business’s revenue for the quarter was up 37.6% on a year-over-year basis.

TRADEMARK VIOLATION WARNING: “Equities Analysts Set Expectations for Tabula Rasa Healthcare Inc.’s Q3 2018 Earnings (TRHC)” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/11/14/equities-analysts-set-expectations-for-tabula-rasa-healthcare-inc-s-q3-2018-earnings-trhc.html.

Other equities research analysts have also recently issued research reports about the stock. Chardan Capital raised their target price on shares of Tabula Rasa Healthcare from $19.50 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, August 8th. Robert W. Baird raised their target price on shares of Tabula Rasa Healthcare from $17.00 to $18.00 and gave the stock an “outperform” rating in a report on Tuesday, August 8th. Piper Jaffray Companies restated an “overweight” rating and issued a $20.00 target price (up previously from $19.00) on shares of Tabula Rasa Healthcare in a report on Wednesday, August 9th. UBS AG raised their target price on shares of Tabula Rasa Healthcare from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, August 30th. Finally, Wells Fargo & Company cut shares of Tabula Rasa Healthcare from an “outperform” rating to a “market perform” rating and raised their target price for the stock from $17.00 to $21.00 in a report on Thursday, September 7th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $28.25.

Tabula Rasa Healthcare (NASDAQ TRHC) traded up $1.01 during trading hours on Tuesday, hitting $29.08. 101,700 shares of the stock were exchanged, compared to its average volume of 88,948. Tabula Rasa Healthcare has a 1 year low of $10.51 and a 1 year high of $31.05. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.66 and a current ratio of 0.73.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TRHC. Pier Capital LLC bought a new position in Tabula Rasa Healthcare in the third quarter worth approximately $4,151,000. Wasatch Advisors Inc. bought a new stake in shares of Tabula Rasa Healthcare during the 3rd quarter valued at $4,047,000. EAM Investors LLC bought a new stake in shares of Tabula Rasa Healthcare during the 3rd quarter valued at $3,931,000. Allianz Asset Management GmbH bought a new stake in shares of Tabula Rasa Healthcare during the 3rd quarter valued at $3,801,000. Finally, Paradigm Capital Management Inc. NY bought a new stake in shares of Tabula Rasa Healthcare during the 2nd quarter valued at $1,165,000. Institutional investors and hedge funds own 25.80% of the company’s stock.

In other Tabula Rasa Healthcare news, insider Orsula V. Knowlton sold 8,000 shares of the stock in a transaction that occurred on Wednesday, October 18th. The shares were sold at an average price of $26.68, for a total value of $213,440.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold 24,000 shares of company stock worth $527,920 over the last quarter. Insiders own 45.80% of the company’s stock.

Tabula Rasa Healthcare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.